NKGen Biotech, Inc. Common Stock
NKGN · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $652 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $326 | $0 | $0 | $326 |
| Gross Profit | $326 | $0 | $0 | -$326 |
| % Margin | 50% | – | – | – |
| R&D Expenses | $1,851 | $2,778 | $3,086 | $2,941 |
| G&A Expenses | $3,544 | $4,010 | $4,371 | $4,385 |
| SG&A Expenses | $3,575 | $4,010 | $4,371 | $4,354 |
| Sales & Mktg Exp. | $31 | $0 | $0 | -$31 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,426 | $6,788 | $7,457 | $7,295 |
| Operating Income | -$5,100 | -$6,788 | -$7,457 | -$7,621 |
| % Margin | -782.2% | – | – | – |
| Other Income/Exp. Net | -$24,261 | $13,386 | -$8,631 | $2,239 |
| Pre-Tax Income | -$29,361 | $6,598 | -$16,088 | -$5,382 |
| Tax Expense | $53 | $0 | $0 | $0 |
| Net Income | -$29,414 | $6,598 | -$16,088 | -$5,382 |
| % Margin | -4,511.3% | – | – | – |
| EPS | -0.84 | 0.22 | -0.67 | -0.25 |
| % Growth | -481.8% | 132.8% | -168% | – |
| EPS Diluted | -0.77 | 0.15 | -0.67 | -0.25 |
| Weighted Avg Shares Out | 28,830 | 29,133 | 24,169 | 21,936 |
| Weighted Avg Shares Out Dil | 28,830 | 24,169 | 24,169 | 21,936 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4,912 | $472 | $647 | $1,069 |
| Depreciation & Amortization | -$984 | $332 | $326 | $326 |
| EBITDA | -$15,266 | $7,402 | -$15,115 | -$3,987 |
| % Margin | -2,341.4% | – | – | – |